| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Operating activities: | |||||||||
Net loss | |||||||||
-11,799 | -18,369 | -1,364 | -18,036 | -6,719 | - | - | - | - | -8,409 |
Net loss | |||||||||
- | - | - | - | - | -14,352 | - | - | -23,026 | - |
Net loss | |||||||||
- | - | - | - | - | - | -2,457 | -6,849 | - | - |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Gain on extinguishment of derivative liability | |||||||||
- | - | - | - | - | - | -1,635 | 0 | - | - |
Depreciation and amortization | |||||||||
- | - | - | - | - | - | 675 | 164 | - | - |
Depreciation | |||||||||
97 | 110 | 67 | 25 | - | - | - | - | 119 | - |
Depreciation | |||||||||
- | - | - | - | 8 | 566 | - | - | - | - |
Loss on sale or disposal of assets | |||||||||
- | - | - | -6 | -1 | -6 | - | - | - | - |
Stock-based compensation expense | |||||||||
515 | 1,221 | 1,240 | 1,391 | 594 | 1,606 | - | - | - | - |
Fair value of derivative liabilities in excess of proceeds | |||||||||
- | - | - | - | - | - | 0 | 408 | 19,642 | - |
(Gain) / loss on adjustments to fair value of derivative liability | |||||||||
- | - | - | - | - | - | -8,980 | -6,907 | - | - |
Fair value of common stock exchanged for warrants | |||||||||
- | - | - | - | - | - | 3,069 | 0 | - | - |
Note payable issued for services | |||||||||
- | - | - | - | - | - | 50 | 0 | - | - |
Warrants, options and stock | |||||||||
- | - | - | - | - | - | 4,228 | 3,643 | 2,768 | - |
Common stock issued for advisory services | |||||||||
- | 50 | 50 | 1,409 | 0 | - | 262 | 130 | - | - |
Warrant related expense, change in fair value, and other financing expenses | |||||||||
- | - | 8,976 | 0 | - | - | - | - | - | - |
Abandonment of in-process research and development intangible asset | |||||||||
- | - | - | 951 | 0 | - | - | - | - | - |
Stock warrant expense - noncash | |||||||||
- | - | - | - | - | 47 | - | - | - | - |
Change in deferred income taxes | |||||||||
332 | -437 | -1,055 | -364 | 0 | -2,816 | - | - | - | - |
Amortization of debt issuance costs and debt discount | |||||||||
- | - | - | - | 147 | - | - | - | - | - |
Gain on settlement of property damage | |||||||||
- | - | - | - | - | 243 | - | - | - | - |
Goodwill impairment | |||||||||
- | 6,929 | - | - | - | 0 | - | - | - | - |
Settlement of litigation matter | |||||||||
- | - | - | 2,500 | 0 | - | - | - | - | - |
Non-cash interest expense | |||||||||
- | - | 33 | 38 | 165 | - | - | - | - | - |
Gain on adjustment to fair value of dervative liabilties | |||||||||
- | - | - | - | - | - | - | - | -12,454 | - |
Depreciation and amortization | |||||||||
- | - | - | - | - | - | - | - | - | 49 |
Impairment of Intangible Assets (Excluding Goodwill) | |||||||||
- | - | - | - | - | 6,670 | 1,935 | 1,423 | 1,859 | 650 |
Loss on settlement of note payable - related parties | |||||||||
- | - | - | - | - | -1,907 | - | - | - | - |
Loss on settlement of note payable | |||||||||
- | - | - | - | - | -400 | - | - | - | - |
Non-cash gain on reversal of liabilities | |||||||||
- | - | - | - | - | - | 0 | 79 | -1,000 | - |
Changes in operating assets and liabilities: | |||||||||
Non-cash gain on reversal of liabilities | |||||||||
- | - | - | - | - | - | - | - | -1,000 | - |
Receivable from former officer and director | |||||||||
- | - | - | - | - | - | 69 | 71 | 0 | - |
Value of stock issued in excess of value received and for warrant expense | |||||||||
- | - | - | - | - | - | - | - | - | 2,934 |
Stock issued for services | |||||||||
- | - | - | - | - | - | - | - | 0 | 1,361 |
Stock issued to settle legal disputes | |||||||||
- | - | - | - | - | - | - | - | - | 704 |
Prepaid expenses, deposits and other assets | |||||||||
-426 | 1 | 664 | -319 | 29 | -979 | 0 | -9 | -566 | -608 |
Accrued expense for potential property damage | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Estimated cost of vendor settlement | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Rent liability for facilities no longer occupied | |||||||||
- | - | - | - | - | - | 0 | 1,260 | 0 | - |
Accrued expense for potential property damage | |||||||||
- | - | - | - | - | - | 0 | 300 | - | - |
Estimated cost of vendor settlement | |||||||||
- | - | - | - | - | - | 0 | 300 | - | - |
Obligation to issue stock | |||||||||
- | - | - | - | - | - | 1,854 | 0 | - | - |
Accounts payable, accrued expenses and other liabilities | |||||||||
567 | -275 | -1,663 | 991 | 647 | -3,801 | 130 | -401 | 270 | 457 |
Net cash used in operating activities | |||||||||
-9,858 | -10,772 | -12,332 | -10,768 | -5,185 | -9,030 | -1,184 | -4,310 | -12,024 | -1,981 |
Investment in Or-Genix | |||||||||
- | - | - | - | - | 0 | - | - | - | - |
Purchases of property and equipment | |||||||||
- | - | 447 | 2 | 40 | 50 | - | - | - | - |
Purchases of certificates of deposit | |||||||||
- | - | 10,000 | 0 | - | - | - | - | - | - |
Maturities of certificates of deposit | |||||||||
- | - | 10,000 | 0 | 2,500 | - | - | - | - | - |
Cash received in reverse merger transaction | |||||||||
- | - | - | 8,500 | 0 | - | - | - | - | - |
Capital expenditures | |||||||||
- | - | - | - | - | - | - | - | 124 | 13 |
Payment for CoreTour acquisition | |||||||||
- | - | - | - | - | - | - | - | 502 | - |
Advances to acquisition targets | |||||||||
- | - | - | - | - | - | - | - | 358 | 1,370 |
Net cash used in investing activities | |||||||||
- | - | -447 | 8,498 | 2,459 | -50 | - | - | -985 | -1,384 |
Cash flows provided by financing activities: | |||||||||
Proceeds from sale of common stock, pre-funded warrants and warrants | |||||||||
12,318 | 10,846 | - | - | - | - | - | - | - | - |
Proceeds received from the exercise of common stock warrants | |||||||||
3,888 | - | - | - | - | - | - | - | - | - |
Proceeds from the sale of Series A convertible preferred stock and warrants, net | |||||||||
- | - | 22,129 | 0 | - | - | - | - | - | - |
Repayment of convertible debt | |||||||||
- | 550 | 1,880 | 0 | - | - | - | - | - | - |
Proceeds from the issuance of convertible debt | |||||||||
- | - | - | 1,880 | 2,401 | - | - | - | - | - |
Proceeds on notes payable - related party | |||||||||
- | - | - | - | - | 400 | - | - | - | - |
Proceeds/(payments) on loans payable to officers and a director | |||||||||
- | - | - | - | - | - | - | - | - | 350 |
Proceeds on notes payable | |||||||||
- | - | - | - | - | 0 | - | - | 387 | 25 |
Bank overdraft | |||||||||
- | - | - | - | - | - | - | - | -62 | 54 |
Payments on notes payable to officers and a director | |||||||||
- | - | - | - | - | - | - | - | 611 | - |
Payment of notes payable | |||||||||
- | - | - | - | - | 1,540 | -700 | -3,483 | - | - |
Increase in payables to officers and a director | |||||||||
- | - | - | - | - | - | 0 | 27 | - | - |
Proceeds from the sale of common stock | |||||||||
- | - | - | - | - | 31,849 | 427 | 143 | 3,989 | 2,310 |
Payment of financing costs that were previously classified in accounts payable | |||||||||
162 | 428 | 125 | 54 | 15 | - | - | - | - | - |
Proceeds from issuance of preferred stock | |||||||||
- | - | - | - | - | - | 0 | 870 | 9,406 | 625 |
Net cash provided by financing activities | |||||||||
16,044 | 9,867 | 20,123 | 1,825 | 2,386 | 30,709 | 1,127 | 4,524 | 13,108 | 3,365 |
Net decrease in cash and cash equivalents | |||||||||
6,186 | -905 | 7,343 | -444 | -339 | 21,628 | -57 | 213 | 98 | - |
Supplemental disclosure of cash flow information: | |||||||||
Cash paid for interest | |||||||||
- | 40 | 112 | 0 | - | 677 | 0 | 0 | 0 | 0 |
Supplemental disclosure of non-cash investing and financing activities: | |||||||||
Conversion of accrued dividends related to convertible preferred stock | |||||||||
- | - | 190 | - | - | - | - | - | - | - |
Offering costs in accounts payable and accrued expenses | |||||||||
238 | - | 146 | 126 | 0 | - | - | - | - | - |
Operating lease right of use asset and current and noncurrent liability | |||||||||
334 | - | - | - | - | - | - | - | - | - |
Reclassification of accrued dividends related to the issuance of common stock to Series A convertible preferred stock holders | |||||||||
- | 1,148 | - | - | - | - | - | - | - | - |
Advances to acquisition | |||||||||
- | - | - | - | - | - | 0 | 50 | - | - |
Advances to acquisition | |||||||||
- | - | - | - | - | - | - | - | 0 | - |
Accounts payable | |||||||||
- | - | - | - | - | - | 316 | 414 | -114 | 518 |
Deferred salary | |||||||||
- | - | - | - | - | - | -581 | 1,152 | 68 | 293 |
Accrued interest | |||||||||
- | - | - | - | - | - | -123 | 559 | 406 | 68 |
Reclassification of the fair market value of the Series A warrants | |||||||||
- | - | 13,153 | 0 | - | - | - | - | - | - |
Series A cumulative preferred dividends | |||||||||
- | 85 | 1,252 | - | - | - | - | - | - | - |
Conversion of convertible notes and related accrued interest into common stock | |||||||||
- | - | - | 711 | 19,700 | - | - | - | - | - |
Consideration in connection with RestorGenex Corporation merger transaction | |||||||||
- | - | - | 21,261 | 0 | - | - | - | - | - |
Conversion of accounts payable to notes payable related to Company's outside law firm | |||||||||
- | - | - | - | - | 407 | - | - | - | - |
Issuance of shares of common stock and stock warrants as payment of accounts payable and accrued liabilities | |||||||||
- | - | - | - | - | 1,323 | - | - | - | - |
Issuance of shares of common stock as payment of notes payable | |||||||||
- | - | - | - | - | 580 | - | - | - | - |
Issuance of shares of common stock and stock warrants as payment of notes payable - related parties | |||||||||
- | - | - | - | - | 1,293 | - | - | - | - |
Issuance of warrants as payment for consulting services | |||||||||
- | - | - | - | - | 547 | - | - | - | - |
Acquisition of business in exchange for common stock | |||||||||
- | - | - | - | - | 6,800 | - | - | - | - |
Cash paid during the period for income taxes | |||||||||
- | - | - | - | - | - | 0 | 0 | 0 | 0 |
Conversion of accrued interest into common stock | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Conversion of loans, accrued salary, accrued interest and expenses due to an officer of the company into common stock | |||||||||
- | - | - | - | - | - | - | - | - | 0 |